A
AbbVie
Pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs
About AbbVie
AbbVie Inc. is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines. The company operates in the healthcare sector, primarily targeting patients with serious health conditions. AbbVie's portfolio includes treatments for a wide range of diseases, including immunology, oncology, virology, and neuroscience. The company also has a significant presence in the aesthetics market, offering products for aesthetic treatments.
AbbVie's clients include healthcare providers, hospitals, and clinics, as well as patients who require specialized medications. The company operates in various markets around the world, with a strong presence in North America, Europe, and Latin America.
The business model of AbbVie revolves around extensive research and development (R&D) to create new and effective treatments. The company invests heavily in R&D, with a reported $50 billion investment to date, to ensure a steady pipeline of new products. AbbVie makes money by selling its pharmaceutical products to healthcare providers and directly to patients through prescriptions. Additionally, the company generates revenue from its aesthetic products, which are sold to dermatologists and plastic surgeons.
AbbVie's commitment to improving patient care is evident through its continuous efforts in R&D and its focus on addressing unmet medical needs. The company also emphasizes sustainability and responsibility, aiming for science-based targets to ensure long-term growth.
In summary, AbbVie is a leading biopharmaceutical company dedicated to developing innovative treatments for serious health conditions, serving healthcare providers and patients globally, and generating revenue through the sale of its pharmaceutical and aesthetic products.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1888
- Headquarters
- North Chicago, United States
- Listing
- IPO 2013
- Employees
- 60,250
- Open positions
- 832
- Dealroom signal
- 35.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Supply Chain Management, Biotechnology, Biotech and Pharma, EIT KIC Partners, Horizon Europe
- Business model
- Manufacturing
- Client focus
- b2c
- Investment activity
- 53 companies, latest Sep 2026
- Capital deployed
- $1B
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Aug 2026 | $9.5B | — | Undisclosed | ↗ |
| POST IPO DEBT✓Debt | Feb 2026 | $7.5B | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for AbbVie is 830K monthly website visits, down 17% over the last three months. AbbVie's team grew 11.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Apogee TherapeuticsWaltham, United StatesDevelops advanced biologics for treating inflammatory and immune diseases like atopic dermatitis and asthma
$11Bvaluation
Endlyz TherapeuticsLondon, United KingdomDeveloping therapeutics to restore endo-lysosomal function in neurodegeneration
$8.8Mvaluation
DISCO PharmaceuticalsCologne, GermanyBiotechnological research as well as the development, production and distribution of biotechnological products and solutions of all kinds
$158Mvaluation
Soufflé TherapeuticsWatertown, United StatesTargeted siRNA medicines for genetic and autoimmune diseases
$800Mvaluation
Capstan TherapeuticsSan Diego, United StatesAdvancing cell engineering to develop therapeutics for a broad range of diseases
$2.1Bvaluation
Syndeio BiosciencesIndianapolis, United StatesDeveloping rapid-acting therapies to enhance synaptic health and treat CNS disorders through novel synapse pharmacology
$360Mvaluation
30fivebioMilton, United KingdomSmall-molecule GPR35 inhibitors for gastrointestinal diseases
→
Light Horse TherapeuticsSan Diego, United StatesPrecision gene editing for small molecule drug discovery
$248Mvaluation
CephagenixGlostrup, DenmarkCephagenix is focused on identifying and developing new effective migraine treatments
$40Mvaluation
Nimble TherapeuticsMadison, United StatesNimble Therapeutics is bringing the power of massively parallel chemical synthesis to drug discovery
→
Aliada TherapeuticsBoston, United StatesDeveloping drugs for the treatment of diseases of the central nervous system (cns)
$1.4Bvaluation
Oisin BiotechnologiesSeattle, United StatesA platform drug development company focused on creating drugs to combat a variety of age related diseases
$60Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors1 additional known investor
ARCH Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about AbbVie on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AbbVie’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.